NCT Neuro Master Match - N²M² (NOA-20)

• Status: Recruiting
• Trial end date: 2024-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The objective of N²M² is the improvement of overall survival of patients with glioblastoma with an unmethylated MGMT promoter based on molecular characterization and use of targeted compounds in a modern trial design. The progression-free survival rate at six months (PFS-6) will be used to make decisions.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Heidelberg
• Collaborators: German Cancer Aid; German Cancer Research Center; National Center for Tumor Diseases, Heidelberg
• Treatments: Atezolizumab; Everolimus; Palbociclib; Sirolimus

Criteria

Main Inclusion Criteria:

• Histologically confirmed, newly diagnosed glioblastoma (astrocytoma World Health Organization (WHO) grade IV) with unmethylated MGMT promoter determined by one of the accepted methods (qPCR, pyrosequencing, methylation array) and without mutation of the isocitrate dehydrogenase genes

• Open biopsy or resection

• Craniotomy or intracranial biopsy site must be adequately healed

• Informed consent

• Standard MRI ≤ 72 (+ 12 h) post-surgery according to the present national and international guidelines

• Availability of fresh-frozen tissue, formalin-fixed, paraffin-embedded (FFPE) tissue, and blood

• Patients eligible for RT at 60 Gy in 2 Gy fractions according to the local Standard of Care

• Age: ≥18 years

• Karnofsky performance status (KPS) ≥70%

• Life expectancy > 6 months

• All female patients with reproductive potential must have a negative pregnancy test (serum or urine) within 6 days prior to start of therapy. All female patients must be surgically sterile or must agree to use adequate contraception during the period of therapy and 6 months after the end of study treatment, or women must be postmenopausal for at least 2 years. Acceptable methods of contraception comprise barrier contraception combined with a medically accepted contraceptive method for the female patient (e.g. intra-uterine device with spermicide, hormonal contraceptive since at least 2 month). Female patients must agree not to donate lactation during treatment and until 6 months after end of treatment

• Male patients willing to use contraception (condoms with spermicidal jellies or cream) upon study entry and during the course of the study and 3 months after the end of the study, have undergone vasectomy, or are practicing total abstinence. Sperm donation is not permitted for the same time interval.

Main Exclusion Criteria:

• Abnormal (≥ Grade 2 CTCAE v5.0) laboratory values for hematology, liver or renal function.

• HIV infection or active Hepatitis B or C infection, or active infections requiring oral or intravenous antibiotics or that can cause a severe disease and pose a severe danger to lab personnel working on patients' blood or tissue (e.g. rabies).

• Prior therapy for glioma (except surgery and steroids) including but not limited to carmustine wafers and immunotherapy.

• Concurrent participation in another interventional clinical trial studying a drug or treatment regimen.

• Insufficient tumor material for molecular diagnostics

• Pregnant and lactating women

• History of hypersensitivity to any of the additives of the study drug formulations

• Co-administration of anti-cancer therapies other than those administered/allowed in this study

• Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the patient in this study

• Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the patient before trial entry